Healthcare of Ontario Pension Plan Trust Fund Reduces Stock Position in Pfizer Inc. (NYSE:PFE)

Healthcare of Ontario Pension Plan Trust Fund lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 9.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 482,168 shares of the biopharmaceutical company’s stock after selling 50,332 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Pfizer were worth $20,738,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of PFE. Core Alternative Capital purchased a new stake in shares of Pfizer in the third quarter worth $30,000. GoalVest Advisory LLC purchased a new stake in Pfizer during the second quarter valued at about $39,000. Tower View Investment Management & Research LLC purchased a new stake in Pfizer during the third quarter valued at about $43,000. USA Financial Portformulas Corp raised its position in Pfizer by 2,697.5% during the third quarter. USA Financial Portformulas Corp now owns 1,119 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 1,079 shares in the last quarter. Finally, Capital Directions Investment Advisors LLC grew its stake in shares of Pfizer by 307.5% during the third quarter. Capital Directions Investment Advisors LLC now owns 1,202 shares of the biopharmaceutical company’s stock valued at $52,000 after buying an additional 907 shares during the last quarter. Hedge funds and other institutional investors own 64.88% of the company’s stock.

In related news, EVP Alexander R. Mackenzie sold 41,360 shares of the company’s stock in a transaction on Thursday, December 2nd. The shares were sold at an average price of $54.26, for a total transaction of $2,244,193.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider John D. Young sold 150,000 shares of Pfizer stock in a transaction on Thursday, November 11th. The stock was sold at an average price of $50.06, for a total transaction of $7,509,000.00. The disclosure for this sale can be found here. Insiders sold a total of 231,360 shares of company stock valued at $11,927,994 in the last ninety days. 0.05% of the stock is currently owned by insiders.

A number of research analysts have recently issued reports on PFE shares. Mizuho raised their price objective on Pfizer from $44.00 to $56.00 and gave the company a “neutral” rating in a research note on Tuesday, December 14th. Truist Securities raised their price objective on Pfizer from $43.00 to $58.00 and gave the company a “buy” rating in a research note on Wednesday, November 24th. The Goldman Sachs Group set a $51.00 target price on Pfizer in a research note on Monday, January 10th. Cowen raised their target price on Pfizer from $56.00 to $70.00 and gave the stock an “outperform” rating in a research note on Monday, December 20th. Finally, Sanford C. Bernstein raised their target price on Pfizer from $44.00 to $65.00 and gave the stock a “market perform” rating in a research note on Monday, January 3rd. Nine research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $57.81.

Shares of NYSE PFE opened at $54.95 on Friday. Pfizer Inc. has a twelve month low of $33.36 and a twelve month high of $61.71. The firm has a market cap of $308.43 billion, a P/E ratio of 16.35, a PEG ratio of 0.74 and a beta of 0.69. The company has a 50 day moving average of $54.39 and a 200 day moving average of $47.49. The company has a quick ratio of 1.18, a current ratio of 1.39 and a debt-to-equity ratio of 0.48.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 2nd. The biopharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.26. Pfizer had a net margin of 27.66% and a return on equity of 30.70%. The firm had revenue of $24.09 billion during the quarter, compared to the consensus estimate of $22.82 billion. During the same quarter in the previous year, the firm posted $0.72 EPS. The company’s revenue for the quarter was up 134.4% compared to the same quarter last year. As a group, equities analysts expect that Pfizer Inc. will post 4.18 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 4th. Investors of record on Friday, January 28th will be issued a $0.40 dividend. The ex-dividend date is Thursday, January 27th. This represents a $1.60 annualized dividend and a yield of 2.91%. This is an increase from Pfizer’s previous quarterly dividend of $0.39. Pfizer’s dividend payout ratio is currently 46.43%.

Pfizer Profile

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Featured Article: What is the Hang Seng index?  

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.